Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo - Part 1 Group 4 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11

NCT06707142
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
TBD11, Placebo
Drug
Lead sponsor
Gates Medical Research Institute
Other
Eligibility
19 Years to 55 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 28, 2026, 9:24 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

NCT03571594
View directory record Official record
Conditions
Acromegaly
Interventions
ONO-5788, ONO-5788 Placebo, Octreotide
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 28, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

NCT06491550
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 28, 2026, 9:24 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants

NCT07570147
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-1451, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 28, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults

NCT00141024
View directory record Official record
Conditions
HIV Infections
Interventions
EP HIV-1043, EP HIV-1090
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 28, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function

NCT02678000
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
LHW090, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Anaheim, California • Lakewood, Colorado • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Sep 28, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

NCT04223349
View directory record Official record
Conditions
Healthy
Interventions
JNJ-70033093, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 28, 2026, 9:24 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Strategies to Augment Ketosis: Ketone Conferred Resiliency Against Sleep Restriction

NCT05519644
View directory record Official record
Conditions
Sleep Deprivation
Interventions
Sleep Deprivation, Heart Rate, Sleep Monitoring, Diet, Exercise Performance, Surveys, McGill Pain Questionnaire, Shortened Profile of Mood States, Pittsburg Sleep Index, Cognitive performance, Marksmanship Performance, Quick Board, Advanced Medical Technologies Inc, Jump Test, CGM/CKM, Blood Draw, Ketone Supplement
Other · Behavioral · Biological + 1 more
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 28, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

NCT06673238
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-722, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Cypress, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 28, 2026, 9:24 PM EDT
Not yet recruiting Phase 2 Interventional

Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction

NCT07538336
View directory record Official record
Conditions
Lung Transplant
Interventions
Emapalumab, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 28, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

NCT04640077
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Cognitive Impairment
Interventions
No Intervention, donanemab
Other · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 90 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
23
States / cities
Phoenix, Arizona • Irvine, California • Bradenton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 28, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy

NCT01185353
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
LY3009104, Placebo, Methotrexate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
31
States / cities
Paradise Valley, Arizona • Peoria, Arizona • Covina, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Sep 28, 2026, 9:24 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

NCT02937168
View directory record Official record
Conditions
Asthma
Interventions
Reslizumab, Fludeoxyglucose F 18 (FDG), Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 28, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer

NCT00613626
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Cisplatin, Etoposide, Placebo, ZD6474
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
19
States / cities
Newark, Delaware • Chicago, Illinois • Galesburg, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Sep 28, 2026, 9:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dose-Response of Gonadal Steroids and Bone Turnover in Older Men

NCT00114114
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Testosterone, Goserelin acetate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 75 Years · Male only
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 28, 2026, 9:24 PM EDT
Not listed Phase 2 Interventional

IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

NCT04933799
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
PF-06650833, Matching Placebo
Drug
Lead sponsor
Giovanni Franchin, M.D, Ph.D
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 28, 2026, 9:24 PM EDT
Active, not recruiting Early Phase 1 Interventional

Efficacy of Spinal Manipulation Therapy or Mindfulness-based Reduction Therapy on Patients With Chronic Low Back Pain

NCT04744883
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Spinal Manipulation Therapy (SMT), Naloxone, Placebo, Mindfulness Based Stress Reduction Therapy (MT)
Other · Drug · Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Sep 28, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

NCT01210495
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Axitinib (AG-013736), Best Supportive Care, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
13
States / cities
Berkeley, California • La Jolla, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 28, 2026, 9:24 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants

NCT07673120
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-313, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 28, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

NCT01686555
View directory record Official record
Conditions
Lupus Erythematosus
Interventions
ABT-199, Placebo
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
11
States / cities
Clearwater, Florida • DeBary, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 28, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860

NCT02546960
View directory record Official record
Conditions
Healthy
Interventions
ExPEC4V (4 : 4 : 4 : 4), ExPEC4V (4 : 4 : 4 : 8), ExPEC4V (8 : 8 : 8 : 8), ExPEC4V (8 : 8 : 8 : 16), ExPEC4V (16 : 16 : 16 : 16), Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
848 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
17
States / cities
Mesa, Arizona • Hollywood, Florida • Leesburg, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Sep 28, 2026, 9:24 PM EDT
Not yet recruiting Phase 1 Interventional

OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis

NCT07221799
View directory record Official record
Conditions
Multiple Sclerosis, Neuropathic Pain
Interventions
glibenclamide, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 28, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities

NCT04167553
View directory record Official record
Conditions
Obese With Comorbidities, Overweight With Comorbidities, Type2 Diabetes
Interventions
HM15136, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 28, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

NCT02413255
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-020, TAK-020 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Sep 28, 2026, 9:24 PM EDT